Atrial Fibrillation Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with permanent atrial fibrillation (an irregular heart rhythm that does not return to normal)
- People aged 65 years or older
- People whose atrial fibrillation has not responded to medications meant to control heart rhythm or heart rate, or who cannot tolerate those medications, or who have already tried a procedure called catheter ablation
- People whose heart failure symptoms fall into a moderate-to-severe range based on a standard medical classification system (confirm with trial site)
- People whose heart is still pumping with more than 40% of its normal pumping strength, as measured within the past 3 months
- People who have had at least one of the following: a hospital stay in the past 12 months where heart failure was the main reason and treatment included an intravenous water tablet, OR a specific blood test result showing elevated heart stress levels within the past 30 days (confirm with trial site)
Who may not be able to join:
- People whose atrial fibrillation causes no symptoms at all
- People whose life expectancy is estimated to be less than 12 months
- People who have moderate to severe disease affecting their heart valves (with some exceptions — confirm with trial site)
- People who have an artificial mechanical replacement valve in one of the heart's right-side valves (the tricuspid valve)
- People with severe long-term kidney disease or who are currently receiving kidney dialysis treatment
- People with a specific type of thickened heart muscle condition that blocks blood flow (obstructive hypertrophic cardiomyopathy)
- People with heart muscle disease caused by certain conditions where abnormal material builds up in the heart, such as amyloidosis, sarcoidosis, or Fabry disease
- People who have had a heart attack or a procedure to open or bypass blocked heart arteries within the past 3 months
- People with severe lung disease, including conditions such as cor pulmonale, irreversible lung disease requiring inhalers, or a need for ongoing oxygen supplementation
- People who already have a pacemaker, defibrillator, or cardiac resynchronisation device implanted, or who have been told they need one
- People who are currently taking part in another randomised clinical trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 82-2-2072-0688
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in NT-proBNP concentration (pg/ml) from baseline to 6-month follow-up
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.